Ask Onix
Finger-prick test trial aims to revolutionize Alzheimer's diagnosis
An international study involving 1,000 volunteers over 60 is investigating whether a simple finger-prick blood test can detect Alzheimer's disease by identifying key biomarkers. The trial spans the UK, US, and Canada and is led by LifeArc and the Global Alzheimer's Platform Foundation.
Why this trial matters
Current diagnostic methods, such as PET brain scans and lumbar punctures, are costly, invasive, and rarely accessible. Only 2% of Alzheimer's patients undergo these tests, leaving many without timely diagnoses. Researchers hope the finger-prick test could provide a faster, more affordable alternative.
"We are looking at three proteins linked to Alzheimer's. Their levels may indicate whether someone is at risk," said Dr. Giovanna Lalli, LifeArc's director of strategy and operations.
Dr. Giovanna Lalli, LifeArc
How the study works
Participants undergo both traditional diagnostic tests and the experimental finger-prick test. The trial measures proteins like amyloid and tau, which can accumulate in the brain years before symptoms appear. Early detection could enable timely intervention, especially as new treatments emerge.
Dr. Emer MacSweeney, a neuro-radiologist recruiting UK volunteers, noted: "A successful test could provide a widely accessible, accurate way to detect Alzheimer's without expensive procedures."
Personal stories drive participation
London GP Dr. Michael Sandberg joined the trial after witnessing his mother's Alzheimer's progression. His negative test result brought relief. "Knowledge is power," he said. "Screening at-risk individuals without invasive methods could transform care."
Sandberg's mother participated in an earlier trial, inspiring his involvement. His experience highlights the emotional toll of the disease and the hope for better diagnostic tools.
Broader implications and challenges
The trial includes cognitively normal individuals, those with mild impairment, and early-stage Alzheimer's patients. At least 25% of participants come from underrepresented groups. Results from all 1,000 volunteers will determine the test's accuracy and potential.
Prof. Fiona Carragher of the Alzheimer's Society emphasized the urgency: "Early diagnosis must be a priority. Blood tests could ensure everyone who needs a diagnosis gets one quickly."
What's next?
The study has enrolled 883 participants, with over 360 completing all tests. Findings are expected by 2028. If successful, the finger-prick test could be used at home, with samples mailed to labs for analysis-no refrigeration required.
This trial builds on growing research into blood-based biomarkers. Last year, US regulators approved a needle-based blood test for Alzheimer's, while another UK study explores blood tests in real-world settings.
